Allergy & Asthma Network Mothers of Asthmatics (AANMA) maintains a listing of clinical research trials for adults and children with asthma and allergies. Check back frequently for new clinical trials in your area.

Note: AANMA does not endorse any company or product on this list. If you’re interested in participating in a clinical trial, we advise you to talk with your physician first. Please do not contact AANMA with questions about a clinical trial posted on this site; call the phone number listed in the specific study instead.

If you are an AANMA Professional Member and have an IRB-approved clinical trial you would like AANMA to post, contact us ^[1]. If you are not a Professional Member, click here to join today ^[2]!

 

• THE PAIR RESEARCH STUDY
• SEVERE ASTHMA RESEARCH PROGRAM (SARP 3)
• DUST ALLERGY RESEARCH STUDY
• YOUR ASTHMA STUDY
• ADD-ON DRUG STUDY (KIA)
• CHILDREN’S ASTHMA RESEARCH STUDY
• VACCINES AND MEDICATIONS IN PREGNANCY SURVEILLANCE SYSTEM (VAMPSS)
• EXPECT Pregnancy Registry: An Observational Research Study of the Use and Safety of XOLAIR® (Omalizumab) During Pregnancy

---

The PAIR Research Study: Adults ages 18-70 with persistent asthma

Purpose of the study

The purpose of this study is to evaluate the safety and effectiveness of an investigational drug taken by mouth in adults with persistent asthma. This is a phase 2, randomized, double-blind, placebo-controlled study. This means that neither you nor your doctor will know which drug you are being given; the study drug or the placebo (sugar pill). Fifty percent of the patients will receive the study drug and fifty percent will receive the placebo.

If you qualify for and agree to participate in the study, you will be given an approved inhaler to take if your asthma symptoms worsen during the study. Staff at the doctor’s office will explain how to use this medication.

If you qualify and agree to participate, there will be at least 9 study visits over 11-12 weeks. During these visits, you will undergo routine health examinations, asthma specific tests, asthma questionnaires, and blood and urine tests. You will also be issued a peak flow meter for breathing tests and an asthma diary in which you will record your results.

The study is dependent on your being able to conduct these breathing tests at home and accurately recording the results.

It is very important that you go to each scheduled study visit, or call the doctor’s office to reschedule if you cannot keep an appointment. You must return any phone call to the doctor’s office as soon as possible.

If you qualify, study-related medical examinations, laboratory tests, and study drug will be provided to you at no cost. You do not need health insurance to participate in this study. As with any clinical research study, you may withdraw at any time and seek other means of treatment.

Eligible Participants

In order to participate in the adult persistent asthma study, you must meet certain criteria determined by the study research team. Some of these include:

• Adult men and women between the ages of 18 to 70
• Have been diagnosed with asthma for at least 6 months
• Diagnosed with asthma before your 40th birthday
• Have not been hospitalized in the last 6 months for any reason
• Have not had cancer in the last 5 years
• Be willing to take a drug and alcohol test
• Be a non-smoker or completely have stopped smoking within the last 6 months
• If female, must not be pregnant, planning to become pregnant or breastfeeding

The study staff will make the full determination of your eligibility to participate in this clinical research study.

Principal investigator

A list of principle investigators can be found at http://www.clinicaltrials.gov/ct2/show/study/NCT01561690?term=502-201&rank=1&show_locs=Y#locn ^[3]

For more information or to enroll

Visit www.thepairstudy.com ^[4]

---

Severe Asthma Research Program (SARP 3)

Purpose of Study

SARP is one of the largest NIH studies currently being conducted in several cities throughout the U.S.  The purpose of this study is to better classify asthma types in order to develop treatments unique to each asthma type.  We are currently conducting the third phase of this study at the University of Wisconsin – Madison.  The study involves up to 13 visits over 3.5 years, and will not involve changing or altering any current medications.  Compensation will be available for your time and travel.

Eligible Participants

• Men and women who have been diagnosed with asthma
• Age 6 years old and over
• Non-smoker
• No other major medical problems

Principal Investigator

Nizar Jarjour, MD
University of Wisconsin – Madison
Pulmonary Research

---

DUST ALLERGY RESEARCH STUDY

Ages 12-17 with dust allergies

Purpose of the study

Dust allergies affect about 20 million Americans. If your child is one of them, consider a local clinical research study for adolescents with dust allergies. Doctors are researching an investigative study drug taken by mouth.

If qualified for this study your child may receive at no cost:

• Investigative allergy drug taken by mouth
• Close monitoring of his or her allergies by your study doctor
• Reimbursement for time and travel

After receiving the first dose of study drug at the doctor’s office under supervision, your child will be able to take the rest of their doses at home. Your child’s health will be monitored throughout his or her participation.

Eligible Participants

To qualify, your child must be between 12 and 17 years old (inclusive) and suffering with dust mite allergies for at least six months. Additional criteria will be assessed by the study doctor to determine your child’s eligibility.

This study is enrolling now. To see if your adolescent may qualify for this study, or to ask questions about potential benefits and risks, please call our staff at 1-888-PRA-TRIALS or visit www.peninsularesearch.com.

Principal Investigator

IRB–approved trial at Copernicus Group

Principal Investigator: Lawrence D. Sher, MD

Peninsula Research Associates

Rolling Hills, CA

 

For more information or to enroll

Call 608-263-0524 or email pulm-research@medicine.wisc.edu ^[5]

Visit http://www2.medicine.wisc.edu/home/asthma/sarpmain ^[6]

Posted January 2013

 

---

YOUR ASTHMA STUDY

Purpose of the study

This research study is being conducted across the U.S. and in more than 20 countries.  The purpose of this study is to evaluate and compare the safety of two asthma medications.  During this 26 week study, safety information will be collected and analyzed in adults and adolescents with asthma.  If you were to participate, you can expect:

• To be randomly assigned to receive either budesonide or Symbicort® for 6 months
• The chances of receiving budesonide are the same as that of receiving Symbicort®
• You will receive a thorough medical evaluation
• You will be followed by a study doctor and their staff during the 26 week period
• You will be asked to provide information about your asthma symptoms and level of activity on a daily basis.

Eligible participants

• Be 12 years of age or older
• Have had asthma for at least one year
• Be treating your asthma daily

The complete list of requirements will be discussed with you by your study doctor.

Principal Investigator

Professor Stephen P Peters, MD, PhD
Prof of Int Med, Pediatrics, and Translational Science
Wake Forest School of Medicine

For more information or to enroll
Call 877-553-6339, or visit
http://yourasthmastudy.com/ ^[7]

Posted November 2012

---

 

ADD-ON DRUG STUDY (KIA)

Purpose of the study
The purpose of this research study is to find out if imatinib (study medication) helps treat asthma. We are testing this medication to see if it helps reduce inflammation (swelling) in the airways when it is taken as an add-on treatment. When your airway is inflamed, your asthma can get worse. Because it is an add-on treatment, it will be given in addition to your regular asthma medications, but will not replace or change your current medications. This study involves up to 17 visits over 8 months with compensation up to $2,000.

Eligible participants

• Men and women using a high-dose inhaled corticosteroid twice per day
• Uncontrolled asthma
• 18-65 years old
• Non-smoker
• No other major medical problems

Principal Investigator
Nizar Jarjour, MD
University of Wisconsin – Madison Pulmonary Research

For more information or to enroll
Call 608-263-0524 or email pulm-research@medicine.wisc.edu ^[5]
Visit http://www2.medicine.wisc.edu/home/pulmasthma/studyfive ^[8]

Posted November 2012

 

 

---

 

CHILDREN’S ASTHMA RESEARCH STUDY

Purpose of the study

Volunteers are needed to participate in an asthma research study testing an investigational drug for asthma. The study will consist of up to 8 office visits over approximately a 4-month period. Qualified volunteers will receive study drug and all related testing at no cost and compensation up to $525 for time and travel.

Eligible participants

• Children ages 5-11 with a diagnosis of asthma AND
• Currently treating their asthma symptoms

Principal investigator

Allan Stillerman, MD, CPI
Clinical Research Institute
Minneapolis, MD

For more information or to enroll

Call Clinical Research Institute, 612-333-2200, ext 5

---

 

VACCINES AND MEDICATIONS IN PREGNANCY SURVEILLANCE SYSTEM (VAMPSS)

Purpose of the study
This is an observational surveillance study to evaluate pregnancy outcomes in pregnant women who have taken asthma medications or received influenza vaccine during pregnancy. In one arm of the study, performed by the Organization of Teratology Information Specialists (OTIS), participants will take part in a telephone interview each trimester and after delivery. No clinic visits are required. VAMPSS is coordinated by the American Academy of Allergy Asthma & Immunology (AAAAI).

Eligible participants
·     Women who are pregnant AND
·     Who have taken a long-acting beta agonist (Foradil, Serevent, Advair, Dulera, Symbicort) or short-acting beta agonist (e.g. albuterol) or received influenza vaccine anytime in pregnancy

Principal investigator
Christina Chambers, PhD, MPH
University of California San Diego, San Diego, CA

For more information or to enroll
Call 877-311-8972
Visit www.otispregnancy.org/asthma-study-s13335 ^[9]

 

 

---

EXPECT Pregnancy Registry: An Observational Research Study of the Use and Safety of XOLAIR^® (Omalizumab) During Pregnancy

Purpose of the study
This is an observational Pregnancy Registry to evaluate pregnancy outcomes in pregnant women who have taken XOLAIR before and/or during pregnancy. Participants will take part in a telephone interview each trimester, at the time of delivery, and when the baby turns 1 year old. No clinic visits are required. Mothers who continue to take XOLAIR while breastfeeding will be asked to participate in one more telephone interview when the baby is 18 months old. Eligible participants will be compensated for each telephone interview.

You do not have to be taking XOLAIR currently to enroll!

Eligible participants

• Women who are pregnant AND
• Who have received Xolair before or during pregnancy

Principal investigator
John M. Thorp Jr., MD
University of North Carolina at Chapel Hill

For more information or to enroll
Call 866-4XOLAIR (496-5247), option 3
Visit www.xolairpregnancyregistry.com ^[10]